Background
==========

Patients receiving anthracyclines (A) and herceptin (H) for treatment of breast cancer require serial monitoring of LV function. Although CMR is considered the gold standard for assessment of volumes and function, most tertiary institutions rely on echocardiography or gated heart pool scans. 2D transthoracic echocardiographic (TTE) image quality relies on appropriate acoustic windows, and accuracy and reproducibility may be particularly limited in this population due to mastectomy and scar. We sought to assess the utility of TTE (LVEF and GLS) compared to CMR in the diagnosis of Stage B heart failure (defined as evidence of structural disease but without signs and symptoms of heart failure \[[@B1]\]) in breast cancer patients receiving cytotoxic chemotherapy.

Methods
=======

In total, 44 patients (30 receiving A and 14 receiving T) underwent cardiac magnetic resonance (CMR) for LV function and advanced 2D echocardiography for LV function and global longitudinal strain (GLS) at 3 time-points (baseline, 3 months and 12 months). We defined stage B heart failure as LVEF \< 10% from baseline, and/or LVEF below 55% and/or GLS \< -19.7\[[@B2]\].

Results
=======

CMR cine assessment of LV function was performed in all 44 patients (100%). Thirty percent (13/44) could not have accurate echocardiographic EF assessment performed at 1 or more time points. Early LV dysfunction was detected by CMR following commencement of chemotherapy (table). There was poor correlation between CMR LVEF and echocardiography EF (graph) with wide limits of agreement (-23.526 to 13.015%). At 12 months, 8 patients (18%) demonstrated stage B heart failure, however none were below the lower limits of normal (\>55%). None of these showed a significant change in TTE EF, however 2 of these patients had GLS \< 19.7 at 12 months.

Conclusions
===========

A significant number (approx. 1/3) of breast cancer patients are unable to have adequate LV function assessment by echocardiography. Subtle LV dysfunction may be a precursor to overt cardiomyopathy and is currently not adequately diagnosed by echocardiography even with inclusion of 2D global longitudinal strain. Serial monitoring of LV function using a non-radiation imaging technique is best performed by CMR.
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  -------------------------------------------------------------
              LVEF (CMR)\       LVEF\        GLS
              (%)               (Echo)\      
                                (%)          
  ----------- ----------------- ------------ ------------------
  Baseline    71.9 ± 6.3        63.8 ± 5.7   -21.4 ± 2.6

                                             

  3 months    66.7 ± 6.7 \*\*   63.5 ± 7.2   -19.5 ± 2.0 \*\*

                                             

  12 months   65.9 ± 7.0 \*\*   62.1 ± .9    -20.1 ± 2.6
  -------------------------------------------------------------
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